Some people may think the retail raise is somehow a disservice...

Some people may think the retail raise is somehow a disservice given the offer price as a discount to SP, and the ratio of 33:1 as being a high bar. My thoughts:

1. The discount is not ridiculous but slightly on a higher end. Given the 100% run up YTD and nearly 200% since November. So I think we shouldn’t just focus on most recent or the ATH price as the offer price, The SP can easily increase 10% in a day or two which can make up for lost ground but shouldn’t be a major concern. In fact I think the SP will temporarily fall to the offer price and post April head north (if not before).

2. Given the total $ value of the raise I certainly think that the company is well positioned to execute on its future trials (looking forward to any new programs like breast cancer) and have a strong position in any M&A discussion.

3. Given the current dilution we can be reasonably confident there will be no further dilution at least until end of 2025.

4.I only hope the instos don’t keep filling the sell side or lend it for shorting but are instead LTSH.

@Davisite - thoughts on the CR?